Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy.

​   The New England Journal of Medicine: Search Results in Dermatology